The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.